Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryHealth Care Technology
SectorMedical
Phone415-910-5717
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees16
Next Earnings Date2/11/2020 (Estimated)
OptionableNot Optionable
Cortexyme (NASDAQ:CRTX) Frequently Asked Questions
What is Cortexyme's stock symbol?
Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."
How were Cortexyme's earnings last quarter?
Cortexyme, Inc. (NASDAQ:CRTX) issued its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.00. View Cortexyme's Earnings History.
When is Cortexyme's next earnings date?
What price target have analysts set for CRTX?
3 brokers have issued 12 month price objectives for Cortexyme's stock. Their forecasts range from $14.00 to $53.00. On average, they anticipate Cortexyme's stock price to reach $34.25 in the next year. This suggests that the stock has a possible downside of 37.7%. View Analyst Price Targets for Cortexyme.
What is the consensus analysts' recommendation for Cortexyme?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cortexyme.
Has Cortexyme been receiving favorable news coverage?
Media stories about CRTX stock have trended very negative on Tuesday, InfoTrie reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cortexyme earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Cortexyme.
Are investors shorting Cortexyme?
Cortexyme saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 1,550,000 shares, an increase of 39.6% from the December 31st total of 1,110,000 shares. Based on an average daily trading volume, of 165,000 shares, the days-to-cover ratio is presently 9.4 days. Approximately 17.2% of the company's stock are sold short. View Cortexyme's Current Options Chain.
Who are some of Cortexyme's key competitors?
What other stocks do shareholders of Cortexyme own?
Who are Cortexyme's key executives?
Cortexyme's management team includes the folowing people:
- Ms. Casey C. Lynch, Co-Founder, Chairman, Pres & CEO (Age 45)
- Mr. Stephen S. Dominy, Co-Founder, Chief Scientific Officer & Director (Age 63)
- Ms. Kristen Gafric, Co-Founder, Sr. VP of Legal & Admin. and Sec. (Age 43)
- Mr. Christopher P. Lowe, CFO & Treasurer (Age 48)
- Dr. Michael J. Detke, Chief Medical Officer (Age 52)
When did Cortexyme IPO?
(CRTX) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.
Who are Cortexyme's major shareholders?
Cortexyme's stock is owned by many different of retail and institutional investors. Top institutional investors include Atlas Capital Advisors LLC (0.01%). Company insiders that own Cortexyme stock include Epiq Capital Group, Llc and Pfizer Inc. View Institutional Ownership Trends for Cortexyme.
Which institutional investors are buying Cortexyme stock?
CRTX stock was purchased by a variety of institutional investors in the last quarter, including Atlas Capital Advisors LLC. Company insiders that have bought Cortexyme stock in the last two years include Epiq Capital Group, Llc and Pfizer Inc. View Insider Buying and Selling for Cortexyme.
How do I buy shares of Cortexyme?
Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cortexyme's stock price today?
One share of CRTX stock can currently be purchased for approximately $55.00.
How big of a company is Cortexyme?
What is Cortexyme's official website?
How can I contact Cortexyme?
Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 415-910-5717 or via email at [email protected]
MarketBeat Community Rating for Cortexyme (NASDAQ CRTX)
MarketBeat's community ratings are surveys of what our community members think about Cortexyme and other stocks. Vote "Outperform" if you believe CRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
